Corporate Presentation

Obesity Survodutide In a 46-week Phase 2 trial in obesity, survodutide dose-dependently reduced body weight by up to 18.7% Phase 2 trial of survodutide in people who were overweight or had obesity ZEAL& ZEALAND PHARMA Boehringer Ingelheim Mean relative change at Week 46 (%) Adjusted mean (95% CI) change in body weight (%) 0 -2 -4 46 -6 -8 -10 -12 -14 -16 -18 TH THH НОЯ -20 -22 0 2 Baseline 6 T I Placebo (n=76) -2.0% T T T T T 王 Survodutide 0.6 mg -6.8% HH H H+H I I QW (n=88) THIOH THI 8 10 12 14 16 18 20 24 Week -8 28 32 36 3.5 40 -0 46 Survodutide 2.4 mg -13.6% QW (n=92) Survodutide 3.6 mg -16.7% QW (n=71) Survodutide 4.8 mg QW (n=54) -18.7% Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries). Source: Figure adapted from Le Roux et al. Oral presentation (51-OR) at ADA 83rd Scientific Sessions, June 23-26, 2023, San Diego, CA. Analysis based on dose reached at the end of treatment regardless of the dose assigned at randomization. Cl=confidence interval; QW-once-weekly. 26

View entire presentation